<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750800</url>
  </required_header>
  <id_info>
    <org_study_id>P15-673</org_study_id>
    <nct_id>NCT02750800</nct_id>
  </id_info>
  <brief_title>Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary</brief_title>
  <acronym>VALUE</acronym>
  <official_title>Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AdWare Research Kft.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluate the effect of adalimumab with patient support program (PSP) on
      clinical, health economic, patient reported outcomes in patients with rheumatoid arthritis,
      ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease and ulcerative
      colitis in the routine clinical setting in Hungary.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2016</start_date>
  <completion_date type="Actual">April 3, 2018</completion_date>
  <primary_completion_date type="Actual">April 3, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline (month 0) in 36-Item Short Form Health Survey, Version 2.0 (SF-36 V2) Physical Component Score (PCS)</measure>
    <time_frame>From Month 0 to 12</time_frame>
    <description>SF-36 V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQL). It consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. Participants self-report on items in a subscale that have choices per item. Scoring is done for both PCS subscale scores and summary scores; for each, the range is 0 (worst HRQL) to 100 (best HRQL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (month 0) in total Satisfaction with Information About Medicines Scale (SIMS) score</measure>
    <time_frame>From Month 0 to 12</time_frame>
    <description>SIMS assesses whether the individual has received enough information about a range of topics relating to prescribed medication. Scores range from 0 to 17 with high scores indicating a high degree of overall satisfaction with the amount of medication information received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (month 0) in total Morisky Medication Adherence Scale, 4 questions (MMAS-4) score</measure>
    <time_frame>From Month 0 to 12</time_frame>
    <description>MMAS-4 is a tool to screen for compliance in Immune-mediated Inflammatory Disease (IMID) patients. It consists of four questions evaluating drug intake habits in patients on chronic therapies with a scoring scheme of &quot;Yes&quot; = 0 and &quot;No&quot; = 1. The items are summed to give a range of scores evaluated as high adherence (0), medium adherence (1-2) or low adherence (3-4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (month 0) in EuroQol five-dimension scale (EQ-5D-5L) quality of life score</measure>
    <time_frame>From Month 0 to 12</time_frame>
    <description>EQ-5D-5L is a widely-used survey instrument for measuring economic preferences for health states, a standardized, self-administered, generic instrument to measure health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline (month 0) in Work Productivity and Activity Impairment (WPAI) Specific Health Problem (SHP) score</measure>
    <time_frame>From Month 0 to 12</time_frame>
    <description>This is a patient-reported quantitative assessment of the amount of absenteeism, presenteeism and daily activity impairment attributable to a specific health problem.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (month 0) in total Treatment Satisfaction Questionnaire for Medication (TSQM)-1.4 score</measure>
    <time_frame>From Month 0 to 12</time_frame>
    <description>TSQM is a generic measure of treatment satisfaction for medication, was rigorously developed with sound psychometric properties. TSQM Ver 1.4 (14 items) includes domains like effectiveness, side effects, convenience and global satisfaction.</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">429</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Psoriasis</condition>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Patients with psoriatic arthritis</arm_group_label>
    <description>Patients with psoriatic arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis</arm_group_label>
    <description>Patients with rheumatoid arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Crohn's disease</arm_group_label>
    <description>Patients with Crohn's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with ulcerative colitis</arm_group_label>
    <description>Patients with ulcerative colitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with ankylosing spondylitis</arm_group_label>
    <description>Patients with ankylosing spondylitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with psoriasis</arm_group_label>
    <description>Patients with psoriasis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis
        (PsA), psoriasis (Ps), Crohn's disease (CD) and ulcerative colitis (UC).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA, AS, PsA, Ps, CD or UC by treating physician.

          -  RA, AS, PsA, Ps, UC or CD patients whom adalimumab treatment is indicated as per local
             Summary of Product Characteristics (SmPC) and professional/reimbursement guidelines.

          -  Subjects assigned to adalimumab treatment not more than 1 month prior to inclusion.

          -  Patient to whom participation in AbbVie CARE 2.0 Patient Support Program (PSP) program
             was offered and patient decided to join and has started the PSP.

          -  Patients willing to be involved in the study and to sign patient informed consent form
             (ICF) and subject information form (SIF) in order to allow use and disclosure of
             his/her personal health information.

        Exclusion Criteria:

          -  Patients who cannot be treated with adalimumab according to the local adalimumab SmPC
             and local professional and reimbursement guidelines.

          -  Patients treated with &gt; 1 prior biologic DMARD for RA, AS, PsA, Ps, UC or CD.

          -  Prior treatment with adalimumab for more than 1 month.

          -  Patients currently participating in other clinical research.

          -  Patients who are unwilling or unable to complete the quality of life and other patient
             reported questionnaires.

          -  Patients who choose not to participate in ABBVIE Care 2.0.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem</name>
      <address>
        <city>Pécs</city>
        <state>Pecs</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovszky Egyetemi Oktatókórház</name>
      <address>
        <city>Szombathely</city>
        <state>Vas</state>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MH Honvedkorhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Janos Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Koz</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korh</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Pandy Kalman Korh</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hevizgyogyfurdo es Szent Andra</name>
      <address>
        <city>Heviz</city>
        <zip>8380</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktat</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAZ Megyei E.O. Korhaz</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUNIKO Egeszsegugyi Szolgaltat</name>
      <address>
        <city>Miskolc</city>
        <zip>3533</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josa Andras Oktato Korhaz</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Korh</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tolna Megyei Onkormanyzat Bala</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Ankylosing spondylitis</keyword>
  <keyword>Psoriatic arthritis</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Crohn's disease</keyword>
  <keyword>Ulcerative colitis</keyword>
  <keyword>Patient support program</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Patient related outcomes</keyword>
  <keyword>Observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

